Search Results

Enlaces a videos educativosSeleccione un tema para mostrar el video y luego haga clic en el reproductor para verlo. Resumen de los tratamientos contra el cáncerLo que puede esperar al comenzar el tratamiento. https://www.youtube.com/watch?v=VME-WEgtEGo Pérdida del cabelloEsto es lo que puede esperar durante el tratamiento. https://www.youtube.com/watch?v=x4v617ODGGE Cambios en la piel y las uñasConsejos generales para…

Dr. Luqman Dad, MD, MBA, is a board-certified Radiation Oncologist, healthcare leader, and educator. He serves as Service Line Chief of Radiation Oncology for Maryland Oncology Hematology and Medical Director of Radiation Oncology for Adventist Health at White Oak and Shady Grove. A Maryland native, Dr. Dad returns after serving at Columbia University Irving Medical…

When you or a loved one is diagnosed with cancer, life changes instantly. Priorities shift to treatments, doctor visits, medications, managing symptoms, and learning to live with a new level of uncertainty. Whether your journey included chemotherapy, radiation, surgery, immunotherapy, or a combination of all of them, you likely spent months devoting your time and…

An Interventional, Open-Label, Randomized, Multicenter, Phase 3 Study of PF-07248144 Plus Fulvestrant Compared to Investigator’s Choice of Therapy in Adult Participants with Hormone Receptor-Positive, HER2-Negative Advanced/Metastatic Breast Cancer Whose Disease Progressed After Prior CDK4/6 Inhibitor-based Therapy MOA: PF-07248144 is a KAT6A inhibitor Key Eligibility Criteria: HR+ /HER2-negative (IHC 0/1+, IHC 2+ & ISH-) LA/met BC…

BNT324-03 A Phase III, randomized, open-label trial of BNT324 versus docetaxel with prednisone/prednisolone in metastatic castration-resistant prostate cancer MOA: BNT324 is an ADC composed of a anti-human B7-H3 IgG1 mAb covalently linked to a topo I inhibitor (P1021) via a tetrapeptide based cleavable linker. Key Eligibility Criteria: Subjects must have histological, pathological, and/or cytological confirmation…